In Canada, veterans suffer from chronic pain at twice the rate of the general population. This pain is often linked to post-traumatic stress disorder (PTSD), and both have a major impact on their quality of life. The autonomic nervous system (ANS) plays a key role in these pathologies, making its modulation a promising therapeutic target. Virtual reality (VR) is already being used to alleviate pain and PTSD in veterans, mainly by modulating ANS reactivity. Two types of VR exist: prolonged exposure (desensitization) and the calming effect, the latter being better tolerated and more suitable for rebalancing the ANS. However, its effects on pain remain modest and temporary. To reinforce these benefits, it is proposed to combine VR with a new approach called cranial nerve non-invasive neuromodulation (CN-NINM), an innovative technique that allows the generation of a direct flow of neuronal impulses via the stimulation of the tongue. The goal of this project is therefore to document the efficacy of VR and the combination of VR and CN-NINM on pain and ANS in veterans suffering from chronic pain and PTSD. VR, CN-NINM and the combination of the two will be applied for 20 minutes. Clinical pain, experimental pain and ANS reactivity will be assessed before and after the interventions. At the end of this study, it is expected that the investigators will be able to document the type of effect CN-NINM could have, and that it could become a complementary therapeutic option.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Recruitment rate for the project
Timeframe: Information will be assessed at the end of the recruitment period, at week 28
Refusal to participate and the reasons
Timeframe: Information will be assessed throughout the project recruitment period (average of 7 months)
Dropped out rate of the project in percent
Timeframe: Information will be assessed through project completion, an average of 9 months
Adherence to the interventions (VR, VR + CN-NINM, VR + CN-NINM placebo) in percent
Timeframe: Information will be assessed through study completion, an average of 9 months
Safety-related informations for each intervention as assessed by a questionnaire
Timeframe: Information will be assessed through study completion, an average of 9 months